Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2016, Article ID 5361569, 6 pages
http://dx.doi.org/10.1155/2016/5361569
Review Article

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature

Department of Dermatology, Ministry of Health Diskapi Yildirim Beyazit Education and Research Hospital, 06110 Ankara, Turkey

Received 30 November 2015; Revised 7 February 2016; Accepted 15 February 2016

Academic Editor: Jean Kanitakis

Copyright © 2016 Bilgen Gençler and Müzeyyen Gönül. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. A. M. Heideman, I. Lurkin, M. Doeleman et al., “KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA,” The Journal of Molecular Diagnostics, vol. 14, no. 3, pp. 247–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. L. A. Dossett, R. R. Kudchadkar, and J. S. Zager, “BRAF and MEK inhibition in melanoma,” Expert Opinion on Drug Safety, vol. 14, no. 4, pp. 559–570, 2015. View at Publisher · View at Google Scholar
  3. B. Hagen and V. A. Trinh, “Managing side effects of vemurafenib therapy for advanced melanoma,” Journal of the Advanced Practitioner in Oncology, vol. 5, no. 6, pp. 400–410, 2014. View at Google Scholar
  4. M. S. Chapman and J. N. Miner, “Novel mitogen-activated protein kinase kinase inhibitors,” Expert Opinion on Investigational Drugs, vol. 20, no. 2, pp. 209–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. K. T. Flaherty, I. Puzanov, K. B. Kim et al., “Inhibition of mutated, activated BRAF in metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 9, pp. 809–819, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Sosman, K. B. Kim, L. Schuchter et al., “Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib,” The New England Journal of Medicine, vol. 366, no. 8, pp. 707–714, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Halaban, W. Zhang, A. Bacchiocchi et al., “PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells,” Pigment Cell & Melanoma Research, vol. 23, no. 2, pp. 190–200, 2010. View at Publisher · View at Google Scholar
  8. P. B. Chapman, A. Hauschild, C. Robert et al., “Improved survival with vemurafenib in melanoma with BRAF V600E mutation,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2507–2516, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Hauschild, J.-J. Grob, L. V. Demidov et al., “Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial,” The Lancet, vol. 380, no. 9839, pp. 358–365, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. C. H. Johansson and S. E. Brage, “BRAF inhibitors in cancer therapy,” Pharmacology and Therapeutics, vol. 142, no. 2, pp. 176–182, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. M. E. Lacouture, M. Duvic, A. Hauschild et al., “Analysis of dermatologic events in vemurafenib-treated patients with melanoma,” Oncologist, vol. 18, no. 3, pp. 314–322, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. G. S. Falchook, G. V. Long, R. Kurzrock et al., “Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial,” The Lancet, vol. 379, no. 9829, pp. 1893–1901, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. P. A. Ascierto, D. Minor, A. Ribas et al., “Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 31, no. 26, pp. 3205–3211, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Sanlorenzo, A. Choudhry, I. Vujic et al., “Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma,” Journal of the American Academy of Dermatology, vol. 71, no. 6, pp. 1102–1109, 2014. View at Publisher · View at Google Scholar
  15. L. Peuvrel, G. Quéreux, M. Saint-Jean et al., “Profile of vemurafenib-induced severe skin toxicities,” Journal of the European Academy of Dermatology and Venereology, vol. 30, no. 2, pp. 250–257, 2016. View at Publisher · View at Google Scholar
  16. M. Munch, L. Peuvrel, A. Brocard et al., “Early-onset vemurafenib-Induced DRESS syndrome,” Dermatology, vol. 232, no. 1, pp. 126–128, 2016. View at Publisher · View at Google Scholar
  17. L. Boussemart, E. Routier, C. Mateus et al., “Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients,” Annals of Oncology, vol. 24, no. 6, pp. 1691–1697, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. P. L. Mattei, M. B. Alora-Palli, S. Kraft, D. P. Lawrence, K. T. Flaherty, and A. B. Kimball, “Cutaneous effects of BRAF inhibitor therapy: a case series,” Annals of Oncology, vol. 24, no. 2, pp. 530–537, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Anforth, G. Carlos, A. Clements, R. Kefford, and P. Fernandez-Peñas, “Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks,” The British Journal of Dermatology, vol. 172, no. 1, pp. 239–243, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. C. M. Wang, K. F. Fleming, and S. Hsu, “A case of vemurafenib-induced keratosis pilaris-like eruption,” Dermatology Online Journal, vol. 18, no. 4, p. 7, 2012. View at Google Scholar · View at Scopus
  21. E. Y. Chu, K. A. Wanat, C. J. Miller et al., “Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study,” Journal of the American Academy of Dermatology, vol. 67, no. 6, pp. 1265–1272, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. J. J. Park, E. B. Hawryluk, S. R. Tahan, K. Flaherty, and C. C. Kim, “Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma,” JAMA Dermatology, vol. 150, no. 3, pp. 307–311, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. M. C. Garrido, C. Gutierrez, E. Riveiro-Falkenbach, P. Ortiz, and J. L. Rodriguez-Peralto, “BRAF inhibitor–induced antitumoral granulomatous dermatitis eruption in advanced melanoma,” The American Journal of Dermatopathology, vol. 37, no. 10, pp. 795–798, 2015. View at Publisher · View at Google Scholar
  24. J. D. Rinderknecht, S. M. Goldinger, S. Rozati et al., “RASopathic skin eruptions during vemurafenib therapy,” PLoS ONE, vol. 8, no. 3, Article ID e58721, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. C. M. Reyes-Habito and E. K. Roh, “Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy,” Journal of the American Academy of Dermatology, vol. 71, no. 2, pp. 217.e1–217.e11, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. S. J. Welsh and P. G. Corrie, “Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma,” Therapeutic Advances in Medical Oncology, vol. 7, no. 2, pp. 122–136, 2015. View at Publisher · View at Google Scholar
  27. R. Dummer, J. Rinderknecht, and S. M. Goldinger, “Ultraviolet a and photosensitivity during vemurafenib therapy,” The New England Journal of Medicine, vol. 366, no. 5, pp. 480–481, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Su, A. Viros, C. Milagre et al., “RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors,” The New England Journal of Medicine, vol. 366, no. 3, pp. 207–215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. C. Mandrell and D. J. Santa Cruz, “Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma?” Seminars in Diagnostic Pathology, vol. 26, no. 3, pp. 150–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Zimmer, U. Hillen, E. Livingstone et al., “Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF Inhibition,” Journal of Clinical Oncology, vol. 30, no. 19, pp. 2375–2383, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. P. R. Cohen, A. Y. Bedikian, and K. B. Kim, “Appearance of new vemurafenib-associated melanocytic nevi on normal-appearing skin: case series and a review of changing or new pigmented lesions in patients with metastatic malignant melanoma after initiating treatment with vemurafenib,” The Journal of Clinical and Aesthetic Dermatology, vol. 6, no. 5, pp. 27–37, 2013. View at Google Scholar · View at Scopus
  32. H. A. Haenssle, S. L. Kraus, F. Brehmer et al., “Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy,” Archives of Dermatology, vol. 148, no. 10, pp. 1183–1185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Dalle, N. Poulalhon, and L. Thomas, “Vemurafenib in melanoma with BRAF V600E mutation,” The New England Journal of Medicine, vol. 365, no. 15, pp. 1448–1449, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. R. M. Anforth, G. R. M. Carlos, R. A. Scolyer, S. Chou, and P. Fernandez-Peñas, “Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma,” Melanoma Research, vol. 25, no. 1, pp. 91–94, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Gebhardt, J. Staub, A. Schmieder, S. Utikal, and J. Utikal, “Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib,” Acta Dermato-Venereologica, vol. 95, no. 1, pp. 96–97, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Houriet, N. D. Klass, H. Beltraminelli, L. Borradori, and P. A. Oberholzer, “Localized epidermal cysts as a radiation recall phenomenon in a melanoma patient treated with radiotherapy and the BRAF inhibitor vemurafenib,” Case Reports in Dermatology, vol. 6, no. 3, pp. 213–217, 2014. View at Publisher · View at Google Scholar
  37. C. J. Anker, A. Ribas, A. H. Grossmann et al., “Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma,” Journal of Clinical Oncology, vol. 31, no. 17, pp. e283–e287, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. M. C. Garrido, E. Riveiro-Falckenbach, Y. Ruano, P. Ortiz, and J. L. Rodriguez-Peralto, “Primary cutaneous small/medium CD4+ T-Cell lymphoma occurring during treatment with vemurafenib for advanced melanoma,” American Journal of Dermatopathology, vol. 37, no. 6, pp. 440–443, 2015. View at Publisher · View at Google Scholar · View at Scopus